We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Sends Untitled Letter to Collegium Over Extended Release Oxycodone
FDA Sends Untitled Letter to Collegium Over Extended Release Oxycodone
The FDA’s Office of Prescription Drug Promotion sent an untitled letter to Collegium Pharmaceutical of Canton, Massachusetts for downplaying the risks of its extended release opioid drug Xtampza ER in an exhibit booth at an American Society of Health-System Pharmacists meeting last summer.